nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—SLC22A2—Vinblastine—head and neck cancer	0.311	0.673	CbGbCtD
Amantadine—ABCB1—Vinblastine—head and neck cancer	0.0828	0.179	CbGbCtD
Amantadine—ABCB1—Docetaxel—head and neck cancer	0.0682	0.148	CbGbCtD
Amantadine—Slurred speech—Fluorouracil—head and neck cancer	0.012	0.0336	CcSEcCtD
Amantadine—Pulmonary oedema—Hydroxyurea—head and neck cancer	0.00664	0.0186	CcSEcCtD
Amantadine—Disorientation—Hydroxyurea—head and neck cancer	0.00605	0.0169	CcSEcCtD
Amantadine—Renal failure acute—Hydroxyurea—head and neck cancer	0.00586	0.0164	CcSEcCtD
Amantadine—Leukocytosis—Fluorouracil—head and neck cancer	0.00571	0.016	CcSEcCtD
Amantadine—Dysarthria—Fluorouracil—head and neck cancer	0.00568	0.0159	CcSEcCtD
Amantadine—Coma—Fluorouracil—head and neck cancer	0.0049	0.0137	CcSEcCtD
Amantadine—Euphoric mood—Fluorouracil—head and neck cancer	0.00461	0.0129	CcSEcCtD
Amantadine—Photosensitivity—Fluorouracil—head and neck cancer	0.00444	0.0124	CcSEcCtD
Amantadine—Neutropenia—Hydroxyurea—head and neck cancer	0.00438	0.0122	CcSEcCtD
Amantadine—Disorientation—Fluorouracil—head and neck cancer	0.00436	0.0122	CcSEcCtD
Amantadine—Agranulocytosis—Vinblastine—head and neck cancer	0.00427	0.0119	CcSEcCtD
Amantadine—Amnesia—Fluorouracil—head and neck cancer	0.00415	0.0116	CcSEcCtD
Amantadine—Cardiac failure—Fluorouracil—head and neck cancer	0.00399	0.0112	CcSEcCtD
Amantadine—Lethargy—Fluorouracil—head and neck cancer	0.00398	0.0111	CcSEcCtD
Amantadine—Osteoarthritis—Fluorouracil—head and neck cancer	0.0039	0.0109	CcSEcCtD
Amantadine—Hallucination—Hydroxyurea—head and neck cancer	0.00373	0.0104	CcSEcCtD
Amantadine—Irritability—Fluorouracil—head and neck cancer	0.00372	0.0104	CcSEcCtD
Amantadine—Cardiac arrest—Fluorouracil—head and neck cancer	0.00371	0.0104	CcSEcCtD
Amantadine—Ataxia—Fluorouracil—head and neck cancer	0.00366	0.0102	CcSEcCtD
Amantadine—Alopecia—Vinblastine—head and neck cancer	0.00363	0.0101	CcSEcCtD
Amantadine—Lightheadedness—Docetaxel—head and neck cancer	0.00347	0.00969	CcSEcCtD
Amantadine—Pulmonary oedema—Docetaxel—head and neck cancer	0.00345	0.00964	CcSEcCtD
Amantadine—Angiopathy—Hydroxyurea—head and neck cancer	0.0034	0.0095	CcSEcCtD
Amantadine—Dysphagia—Fluorouracil—head and neck cancer	0.00337	0.00942	CcSEcCtD
Amantadine—Alopecia—Hydroxyurea—head and neck cancer	0.00331	0.00925	CcSEcCtD
Amantadine—Leukopenia—Vinblastine—head and neck cancer	0.0032	0.00895	CcSEcCtD
Amantadine—Cardiac failure congestive—Docetaxel—head and neck cancer	0.0031	0.00867	CcSEcCtD
Amantadine—Convulsion—Vinblastine—head and neck cancer	0.0031	0.00866	CcSEcCtD
Amantadine—Hypertension—Vinblastine—head and neck cancer	0.00309	0.00863	CcSEcCtD
Amantadine—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00307	0.0086	CcSEcCtD
Amantadine—Visual disturbance—Docetaxel—head and neck cancer	0.00297	0.0083	CcSEcCtD
Amantadine—Leukopenia—Hydroxyurea—head and neck cancer	0.00292	0.00816	CcSEcCtD
Amantadine—Cardiac failure—Docetaxel—head and neck cancer	0.00288	0.00806	CcSEcCtD
Amantadine—Lethargy—Docetaxel—head and neck cancer	0.00287	0.00803	CcSEcCtD
Amantadine—Convulsion—Hydroxyurea—head and neck cancer	0.00282	0.0079	CcSEcCtD
Amantadine—Agranulocytosis—Fluorouracil—head and neck cancer	0.0028	0.00784	CcSEcCtD
Amantadine—Anorexia—Vinblastine—head and neck cancer	0.00278	0.00778	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00276	0.00771	CcSEcCtD
Amantadine—Oedema—Hydroxyurea—head and neck cancer	0.00266	0.00744	CcSEcCtD
Amantadine—Ataxia—Docetaxel—head and neck cancer	0.00264	0.00739	CcSEcCtD
Amantadine—Paraesthesia—Vinblastine—head and neck cancer	0.00262	0.00733	CcSEcCtD
Amantadine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00261	0.0073	CcSEcCtD
Amantadine—Liver function test abnormal—Docetaxel—head and neck cancer	0.0026	0.00726	CcSEcCtD
Amantadine—Skin disorder—Hydroxyurea—head and neck cancer	0.00258	0.00723	CcSEcCtD
Amantadine—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00257	0.00718	CcSEcCtD
Amantadine—Anorexia—Hydroxyurea—head and neck cancer	0.00254	0.00709	CcSEcCtD
Amantadine—Decreased appetite—Vinblastine—head and neck cancer	0.00254	0.00709	CcSEcCtD
Amantadine—Constipation—Vinblastine—head and neck cancer	0.00249	0.00698	CcSEcCtD
Amantadine—Dysphagia—Docetaxel—head and neck cancer	0.00243	0.0068	CcSEcCtD
Amantadine—Arrhythmia—Fluorouracil—head and neck cancer	0.00241	0.00673	CcSEcCtD
Amantadine—Feeling abnormal—Vinblastine—head and neck cancer	0.0024	0.00672	CcSEcCtD
Amantadine—Alopecia—Fluorouracil—head and neck cancer	0.00238	0.00666	CcSEcCtD
Amantadine—Dyspnoea—Hydroxyurea—head and neck cancer	0.00237	0.00663	CcSEcCtD
Amantadine—Somnolence—Hydroxyurea—head and neck cancer	0.00237	0.00661	CcSEcCtD
Amantadine—Dyspepsia—Hydroxyurea—head and neck cancer	0.00234	0.00655	CcSEcCtD
Amantadine—Decreased appetite—Hydroxyurea—head and neck cancer	0.00231	0.00647	CcSEcCtD
Amantadine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.0023	0.00642	CcSEcCtD
Amantadine—Fatigue—Hydroxyurea—head and neck cancer	0.00229	0.00641	CcSEcCtD
Amantadine—Constipation—Hydroxyurea—head and neck cancer	0.00228	0.00636	CcSEcCtD
Amantadine—Neutropenia—Docetaxel—head and neck cancer	0.00227	0.00636	CcSEcCtD
Amantadine—Vision blurred—Fluorouracil—head and neck cancer	0.00221	0.00618	CcSEcCtD
Amantadine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00219	0.00613	CcSEcCtD
Amantadine—Hypersensitivity—Vinblastine—head and neck cancer	0.00215	0.00601	CcSEcCtD
Amantadine—Body temperature increased—Hydroxyurea—head and neck cancer	0.0021	0.00588	CcSEcCtD
Amantadine—Leukopenia—Fluorouracil—head and neck cancer	0.0021	0.00587	CcSEcCtD
Amantadine—Asthenia—Vinblastine—head and neck cancer	0.00209	0.00585	CcSEcCtD
Amantadine—Convulsion—Fluorouracil—head and neck cancer	0.00203	0.00569	CcSEcCtD
Amantadine—Agranulocytosis—Docetaxel—head and neck cancer	0.00202	0.00566	CcSEcCtD
Amantadine—Diarrhoea—Vinblastine—head and neck cancer	0.002	0.00558	CcSEcCtD
Amantadine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00196	0.00548	CcSEcCtD
Amantadine—Confusional state—Fluorouracil—head and neck cancer	0.00193	0.0054	CcSEcCtD
Amantadine—Dizziness—Vinblastine—head and neck cancer	0.00193	0.00539	CcSEcCtD
Amantadine—Urinary tract disorder—Docetaxel—head and neck cancer	0.00192	0.00537	CcSEcCtD
Amantadine—Oedema peripheral—Docetaxel—head and neck cancer	0.00192	0.00536	CcSEcCtD
Amantadine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00192	0.00536	CcSEcCtD
Amantadine—Oedema—Fluorouracil—head and neck cancer	0.00192	0.00536	CcSEcCtD
Amantadine—Asthenia—Hydroxyurea—head and neck cancer	0.00191	0.00534	CcSEcCtD
Amantadine—Urethral disorder—Docetaxel—head and neck cancer	0.00191	0.00533	CcSEcCtD
Amantadine—Nervous system disorder—Fluorouracil—head and neck cancer	0.00188	0.00525	CcSEcCtD
Amantadine—Visual impairment—Docetaxel—head and neck cancer	0.00187	0.00524	CcSEcCtD
Amantadine—Tachycardia—Fluorouracil—head and neck cancer	0.00187	0.00523	CcSEcCtD
Amantadine—Vomiting—Vinblastine—head and neck cancer	0.00185	0.00519	CcSEcCtD
Amantadine—Headache—Vinblastine—head and neck cancer	0.00183	0.00511	CcSEcCtD
Amantadine—Anorexia—Fluorouracil—head and neck cancer	0.00183	0.0051	CcSEcCtD
Amantadine—Diarrhoea—Hydroxyurea—head and neck cancer	0.00182	0.00509	CcSEcCtD
Amantadine—Eye disorder—Docetaxel—head and neck cancer	0.00182	0.00508	CcSEcCtD
Amantadine—Cardiac disorder—Docetaxel—head and neck cancer	0.00181	0.00505	CcSEcCtD
Amantadine—Hypotension—Fluorouracil—head and neck cancer	0.00179	0.005	CcSEcCtD
Amantadine—Angiopathy—Docetaxel—head and neck cancer	0.00177	0.00494	CcSEcCtD
Amantadine—Dizziness—Hydroxyurea—head and neck cancer	0.00176	0.00492	CcSEcCtD
Amantadine—Mediastinal disorder—Docetaxel—head and neck cancer	0.00175	0.0049	CcSEcCtD
Amantadine—Arrhythmia—Docetaxel—head and neck cancer	0.00174	0.00486	CcSEcCtD
Amantadine—Nausea—Vinblastine—head and neck cancer	0.00173	0.00485	CcSEcCtD
Amantadine—Insomnia—Fluorouracil—head and neck cancer	0.00173	0.00484	CcSEcCtD
Amantadine—Paraesthesia—Fluorouracil—head and neck cancer	0.00172	0.00481	CcSEcCtD
Amantadine—Alopecia—Docetaxel—head and neck cancer	0.00172	0.00481	CcSEcCtD
Amantadine—Dyspnoea—Fluorouracil—head and neck cancer	0.00171	0.00477	CcSEcCtD
Amantadine—Mental disorder—Docetaxel—head and neck cancer	0.0017	0.00477	CcSEcCtD
Amantadine—Somnolence—Fluorouracil—head and neck cancer	0.0017	0.00476	CcSEcCtD
Amantadine—Malnutrition—Docetaxel—head and neck cancer	0.00169	0.00474	CcSEcCtD
Amantadine—Vomiting—Hydroxyurea—head and neck cancer	0.00169	0.00473	CcSEcCtD
Amantadine—Dyspepsia—Fluorouracil—head and neck cancer	0.00169	0.00471	CcSEcCtD
Amantadine—Rash—Hydroxyurea—head and neck cancer	0.00168	0.00469	CcSEcCtD
Amantadine—Dermatitis—Hydroxyurea—head and neck cancer	0.00168	0.00469	CcSEcCtD
Amantadine—Headache—Hydroxyurea—head and neck cancer	0.00167	0.00466	CcSEcCtD
Amantadine—Decreased appetite—Fluorouracil—head and neck cancer	0.00166	0.00466	CcSEcCtD
Amantadine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00165	0.00462	CcSEcCtD
Amantadine—Nausea—Hydroxyurea—head and neck cancer	0.00158	0.00442	CcSEcCtD
Amantadine—Feeling abnormal—Fluorouracil—head and neck cancer	0.00158	0.00441	CcSEcCtD
Amantadine—Leukopenia—Docetaxel—head and neck cancer	0.00152	0.00424	CcSEcCtD
Amantadine—Body temperature increased—Fluorouracil—head and neck cancer	0.00151	0.00423	CcSEcCtD
Amantadine—Palpitations—Docetaxel—head and neck cancer	0.0015	0.00419	CcSEcCtD
Amantadine—Convulsion—Docetaxel—head and neck cancer	0.00147	0.0041	CcSEcCtD
Amantadine—Hypertension—Docetaxel—head and neck cancer	0.00146	0.00409	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00143	0.004	CcSEcCtD
Amantadine—Hypersensitivity—Fluorouracil—head and neck cancer	0.00141	0.00395	CcSEcCtD
Amantadine—Dry mouth—Docetaxel—head and neck cancer	0.00141	0.00394	CcSEcCtD
Amantadine—Confusional state—Docetaxel—head and neck cancer	0.00139	0.0039	CcSEcCtD
Amantadine—Anaphylactic shock—Docetaxel—head and neck cancer	0.00138	0.00387	CcSEcCtD
Amantadine—Oedema—Docetaxel—head and neck cancer	0.00138	0.00387	CcSEcCtD
Amantadine—Nervous system disorder—Docetaxel—head and neck cancer	0.00136	0.00379	CcSEcCtD
Amantadine—Pruritus—Fluorouracil—head and neck cancer	0.00135	0.00379	CcSEcCtD
Amantadine—Tachycardia—Docetaxel—head and neck cancer	0.00135	0.00377	CcSEcCtD
Amantadine—Skin disorder—Docetaxel—head and neck cancer	0.00134	0.00375	CcSEcCtD
Amantadine—GRIN1—Post NMDA receptor activation events—MAPK1—head and neck cancer	0.00133	0.00735	CbGpPWpGaD
Amantadine—Anorexia—Docetaxel—head and neck cancer	0.00132	0.00368	CcSEcCtD
Amantadine—Diarrhoea—Fluorouracil—head and neck cancer	0.00131	0.00366	CcSEcCtD
Amantadine—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—head and neck cancer	0.00129	0.00717	CbGpPWpGaD
Amantadine—GRIN2B—Post NMDA receptor activation events—MAPK1—head and neck cancer	0.00129	0.00716	CbGpPWpGaD
Amantadine—Hypotension—Docetaxel—head and neck cancer	0.00129	0.00361	CcSEcCtD
Amantadine—Dizziness—Fluorouracil—head and neck cancer	0.00127	0.00354	CcSEcCtD
Amantadine—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—head and neck cancer	0.00126	0.00699	CbGpPWpGaD
Amantadine—Insomnia—Docetaxel—head and neck cancer	0.00125	0.0035	CcSEcCtD
Amantadine—GRIN1—Alzheimers Disease—CASP8—head and neck cancer	0.00125	0.00693	CbGpPWpGaD
Amantadine—Paraesthesia—Docetaxel—head and neck cancer	0.00124	0.00347	CcSEcCtD
Amantadine—Dyspnoea—Docetaxel—head and neck cancer	0.00123	0.00345	CcSEcCtD
Amantadine—Somnolence—Docetaxel—head and neck cancer	0.00123	0.00344	CcSEcCtD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—MAPK1—head and neck cancer	0.00122	0.00677	CbGpPWpGaD
Amantadine—GRIN2A—Post NMDA receptor activation events—HRAS—head and neck cancer	0.00122	0.00676	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—CASP8—head and neck cancer	0.00122	0.00675	CbGpPWpGaD
Amantadine—Vomiting—Fluorouracil—head and neck cancer	0.00122	0.0034	CcSEcCtD
Amantadine—Dyspepsia—Docetaxel—head and neck cancer	0.00122	0.0034	CcSEcCtD
Amantadine—Rash—Fluorouracil—head and neck cancer	0.00121	0.00338	CcSEcCtD
Amantadine—Dermatitis—Fluorouracil—head and neck cancer	0.00121	0.00337	CcSEcCtD
Amantadine—Decreased appetite—Docetaxel—head and neck cancer	0.0012	0.00336	CcSEcCtD
Amantadine—Headache—Fluorouracil—head and neck cancer	0.0012	0.00335	CcSEcCtD
Amantadine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00119	0.00334	CcSEcCtD
Amantadine—Fatigue—Docetaxel—head and neck cancer	0.00119	0.00333	CcSEcCtD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—MAPK1—head and neck cancer	0.00119	0.0066	CbGpPWpGaD
Amantadine—Constipation—Docetaxel—head and neck cancer	0.00118	0.00331	CcSEcCtD
Amantadine—GRIN2B—ErbB4 signaling events—PIK3CA—head and neck cancer	0.00117	0.0065	CbGpPWpGaD
Amantadine—GRIN2B—Reelin signaling pathway—AKT1—head and neck cancer	0.00114	0.00634	CbGpPWpGaD
Amantadine—GRIN2C—Alzheimers Disease—MAPK3—head and neck cancer	0.00114	0.00632	CbGpPWpGaD
Amantadine—Feeling abnormal—Docetaxel—head and neck cancer	0.00114	0.00319	CcSEcCtD
Amantadine—Nausea—Fluorouracil—head and neck cancer	0.00114	0.00318	CcSEcCtD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—head and neck cancer	0.00112	0.00623	CbGpPWpGaD
Amantadine—Body temperature increased—Docetaxel—head and neck cancer	0.00109	0.00306	CcSEcCtD
Amantadine—GRIN2C—Alzheimers Disease—MAPK1—head and neck cancer	0.00108	0.00601	CbGpPWpGaD
Amantadine—GRIN1—Post NMDA receptor activation events—HRAS—head and neck cancer	0.00106	0.0059	CbGpPWpGaD
Amantadine—GRIN2D—Alzheimers Disease—MAPK3—head and neck cancer	0.00106	0.00588	CbGpPWpGaD
Amantadine—GRIN2B—Post NMDA receptor activation events—HRAS—head and neck cancer	0.00104	0.00575	CbGpPWpGaD
Amantadine—Hypersensitivity—Docetaxel—head and neck cancer	0.00102	0.00285	CcSEcCtD
Amantadine—GRIN2D—Alzheimers Disease—MAPK1—head and neck cancer	0.00101	0.00559	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TYMS—head and neck cancer	0.00101	0.00559	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CEBPA—head and neck cancer	0.000993	0.0055	CbGpPWpGaD
Amantadine—Asthenia—Docetaxel—head and neck cancer	0.000992	0.00277	CcSEcCtD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—head and neck cancer	0.00098	0.00543	CbGpPWpGaD
Amantadine—GRIN1—EPHB-mediated forward signaling—HRAS—head and neck cancer	0.00098	0.00543	CbGpPWpGaD
Amantadine—Pruritus—Docetaxel—head and neck cancer	0.000978	0.00273	CcSEcCtD
Amantadine—GRIN2B—Developmental Biology—CEBPA—head and neck cancer	0.000968	0.00537	CbGpPWpGaD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—head and neck cancer	0.000956	0.0053	CbGpPWpGaD
Amantadine—GRIN2B—EPHB-mediated forward signaling—HRAS—head and neck cancer	0.000956	0.0053	CbGpPWpGaD
Amantadine—MAOB—Biological oxidations—GSTM1—head and neck cancer	0.00095	0.00527	CbGpPWpGaD
Amantadine—Diarrhoea—Docetaxel—head and neck cancer	0.000946	0.00264	CcSEcCtD
Amantadine—DDC—Metabolism—UROD—head and neck cancer	0.000941	0.00522	CbGpPWpGaD
Amantadine—Dizziness—Docetaxel—head and neck cancer	0.000914	0.00256	CcSEcCtD
Amantadine—GRIN2C—Alzheimers Disease—TP53—head and neck cancer	0.000911	0.00505	CbGpPWpGaD
Amantadine—MAOB—Biological oxidations—CYP1A1—head and neck cancer	0.000901	0.00499	CbGpPWpGaD
Amantadine—Vomiting—Docetaxel—head and neck cancer	0.000879	0.00246	CcSEcCtD
Amantadine—Rash—Docetaxel—head and neck cancer	0.000872	0.00244	CcSEcCtD
Amantadine—Dermatitis—Docetaxel—head and neck cancer	0.000871	0.00243	CcSEcCtD
Amantadine—GRIN2A—Alzheimers Disease—MAPK3—head and neck cancer	0.000871	0.00482	CbGpPWpGaD
Amantadine—Headache—Docetaxel—head and neck cancer	0.000866	0.00242	CcSEcCtD
Amantadine—GRIN2D—Alzheimers Disease—TP53—head and neck cancer	0.000847	0.00469	CbGpPWpGaD
Amantadine—GRIN2A—Alzheimers Disease—MAPK1—head and neck cancer	0.000828	0.00459	CbGpPWpGaD
Amantadine—Nausea—Docetaxel—head and neck cancer	0.000821	0.0023	CcSEcCtD
Amantadine—MAOB—Metabolism—UROD—head and neck cancer	0.000792	0.00439	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—MAPK3—head and neck cancer	0.000759	0.00421	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—MAPK3—head and neck cancer	0.00074	0.0041	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—PTGS2—head and neck cancer	0.000739	0.0041	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—MAPK1—head and neck cancer	0.000722	0.004	CbGpPWpGaD
Amantadine—DRD2—Hypothetical Network for Drug Addiction—MAPK3—head and neck cancer	0.000718	0.00398	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—MAPK1—head and neck cancer	0.000704	0.0039	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—VEGFA—head and neck cancer	0.000698	0.00387	CbGpPWpGaD
Amantadine—GRIN2A—Alzheimers Disease—TP53—head and neck cancer	0.000695	0.00385	CbGpPWpGaD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000686	0.0038	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—IL2—head and neck cancer	0.000685	0.0038	CbGpPWpGaD
Amantadine—DRD2—Hypothetical Network for Drug Addiction—MAPK1—head and neck cancer	0.000683	0.00379	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—VEGFA—head and neck cancer	0.000681	0.00377	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CCND1—head and neck cancer	0.000668	0.0037	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.000656	0.00364	CbGpPWpGaD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000638	0.00354	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—TP53—head and neck cancer	0.000606	0.00336	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—TP53—head and neck cancer	0.000591	0.00328	CbGpPWpGaD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000551	0.00305	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—MAPK3—head and neck cancer	0.000551	0.00305	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000542	0.003	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.000541	0.003	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—MAPK1—head and neck cancer	0.000524	0.0029	CbGpPWpGaD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000524	0.0029	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—EGFR—head and neck cancer	0.000524	0.0029	CbGpPWpGaD
Amantadine—GRIN2C—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000516	0.00286	CbGpPWpGaD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000512	0.00284	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—HRAS—head and neck cancer	0.000505	0.0028	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—KISS1—head and neck cancer	0.0005	0.00277	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—HRAS—head and neck cancer	0.000492	0.00273	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—STAT3—head and neck cancer	0.000492	0.00272	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—PTEN—head and neck cancer	0.00049	0.00272	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.00048	0.00266	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—STAT3—head and neck cancer	0.000479	0.00266	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000472	0.00261	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—MAPK3—head and neck cancer	0.00047	0.0026	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.000469	0.0026	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000466	0.00258	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—MAPK3—head and neck cancer	0.000458	0.00254	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000457	0.00253	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—MAPK1—head and neck cancer	0.000447	0.00248	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000446	0.00247	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TP53—head and neck cancer	0.00044	0.00244	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00044	0.00244	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—MAPK1—head and neck cancer	0.000436	0.00241	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000427	0.00237	CbGpPWpGaD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000421	0.00233	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—UROD—head and neck cancer	0.00042	0.00233	CbGpPWpGaD
Amantadine—GRIN2C—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000414	0.0023	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—GRP—head and neck cancer	0.000412	0.00228	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TYMS—head and neck cancer	0.000397	0.0022	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—MAPK1—head and neck cancer	0.000395	0.00219	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000394	0.00218	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—UROD—head and neck cancer	0.000392	0.00217	CbGpPWpGaD
Amantadine—DDC—Metabolism—NAT2—head and neck cancer	0.000391	0.00217	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000385	0.00213	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—MAPK1—head and neck cancer	0.000368	0.00204	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000367	0.00203	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—HRAS—head and neck cancer	0.000359	0.00199	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000358	0.00198	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—CASP8—head and neck cancer	0.000355	0.00197	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—HRAS—head and neck cancer	0.00035	0.00194	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000344	0.0019	CbGpPWpGaD
Amantadine—DDC—Metabolism—DPYD—head and neck cancer	0.000343	0.0019	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000335	0.00186	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TP53—head and neck cancer	0.000334	0.00185	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NAT2—head and neck cancer	0.000329	0.00182	CbGpPWpGaD
Amantadine—DDC—Metabolism—YAP1—head and neck cancer	0.000325	0.0018	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—HRAS—head and neck cancer	0.000317	0.00176	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—AKT1—head and neck cancer	0.000317	0.00176	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—NOTCH1—head and neck cancer	0.000317	0.00176	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000316	0.00175	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—AKT1—head and neck cancer	0.000309	0.00171	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—NOTCH1—head and neck cancer	0.000309	0.00171	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—MAPK1—head and neck cancer	0.000302	0.00167	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—HRAS—head and neck cancer	0.000295	0.00164	CbGpPWpGaD
Amantadine—MAOB—Metabolism—DPYD—head and neck cancer	0.000289	0.0016	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—KISS1—head and neck cancer	0.000282	0.00157	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000276	0.00153	CbGpPWpGaD
Amantadine—MAOB—Metabolism—YAP1—head and neck cancer	0.000274	0.00152	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000269	0.00149	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL2—head and neck cancer	0.000268	0.00149	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—MAPK1—head and neck cancer	0.000263	0.00146	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	0.000263	0.00146	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—VEGFA—head and neck cancer	0.00026	0.00144	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000258	0.00143	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—MAPK1—head and neck cancer	0.000257	0.00142	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KISS1—head and neck cancer	0.000257	0.00142	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000256	0.00142	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—VEGFA—head and neck cancer	0.000253	0.0014	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MAPK3—head and neck cancer	0.000246	0.00136	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—HRAS—head and neck cancer	0.000242	0.00134	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MAPK3—head and neck cancer	0.000239	0.00133	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MAPK1—head and neck cancer	0.000234	0.00129	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—EGFR—head and neck cancer	0.000234	0.00129	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—GRP—head and neck cancer	0.000233	0.00129	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—UROD—head and neck cancer	0.00023	0.00127	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	0.000228	0.00126	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MAPK1—head and neck cancer	0.000228	0.00126	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EGFR—head and neck cancer	0.000228	0.00126	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—HRAS—head and neck cancer	0.000211	0.00117	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GRP—head and neck cancer	0.000211	0.00117	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—HRAS—head and neck cancer	0.000206	0.00114	CbGpPWpGaD
Amantadine—DDC—Metabolism—TYMS—head and neck cancer	0.000195	0.00108	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—PTEN—head and neck cancer	0.000193	0.00107	CbGpPWpGaD
Amantadine—DDC—Metabolism—GSTM1—head and neck cancer	0.000193	0.00107	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—HRAS—head and neck cancer	0.000188	0.00104	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—VEGFA—head and neck cancer	0.000185	0.00103	CbGpPWpGaD
Amantadine—DDC—Metabolism—GPX1—head and neck cancer	0.000185	0.00102	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—STAT3—head and neck cancer	0.000183	0.00102	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP1A1—head and neck cancer	0.000183	0.00101	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—HRAS—head and neck cancer	0.000183	0.00101	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—VEGFA—head and neck cancer	0.000181	0.001	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—STAT3—head and neck cancer	0.000179	0.000991	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000179	0.00099	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MAPK3—head and neck cancer	0.000175	0.000971	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000175	0.000971	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NAT2—head and neck cancer	0.000175	0.000968	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MAPK3—head and neck cancer	0.000171	0.000947	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	0.000168	0.000931	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MAPK1—head and neck cancer	0.000167	0.000924	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EGFR—head and neck cancer	0.000167	0.000924	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000167	0.000923	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TYMS—head and neck cancer	0.000164	0.000911	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NAT2—head and neck cancer	0.000163	0.000902	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GSTM1—head and neck cancer	0.000163	0.000901	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MAPK1—head and neck cancer	0.000163	0.000901	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EGFR—head and neck cancer	0.000162	0.0009	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GPX1—head and neck cancer	0.000156	0.000863	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP1A1—head and neck cancer	0.000154	0.000854	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—DPYD—head and neck cancer	0.000153	0.000849	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KISS1—head and neck cancer	0.000152	0.00084	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	0.00015	0.000833	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—YAP1—head and neck cancer	0.000145	0.000805	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000143	0.000795	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	0.000143	0.000792	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—DPYD—head and neck cancer	0.000143	0.000791	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—MAPK1—head and neck cancer	0.000137	0.000759	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—YAP1—head and neck cancer	0.000135	0.000751	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—head and neck cancer	0.000134	0.000742	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000134	0.000741	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—head and neck cancer	0.000132	0.000731	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—head and neck cancer	0.00013	0.000723	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	0.000129	0.000715	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—MAPK1—head and neck cancer	0.000128	0.000707	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GRP—head and neck cancer	0.000125	0.000692	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	0.000125	0.00069	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT6—head and neck cancer	0.000121	0.000671	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—head and neck cancer	0.000118	0.000655	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—head and neck cancer	0.000115	0.000638	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	0.000112	0.000623	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—head and neck cancer	0.00011	0.000609	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—head and neck cancer	0.000109	0.000603	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—YAP1—head and neck cancer	0.000107	0.000594	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	0.000106	0.00059	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—head and neck cancer	0.000102	0.000568	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	0.000101	0.000561	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	0.000101	0.000561	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NAT2—head and neck cancer	9.54e-05	0.000529	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTEN—head and neck cancer	9.49e-05	0.000526	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—head and neck cancer	9.16e-05	0.000508	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	8.79e-05	0.000487	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TYMS—head and neck cancer	8.72e-05	0.000484	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTM1—head and neck cancer	8.62e-05	0.000478	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	8.5e-05	0.000471	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—DPYD—head and neck cancer	8.36e-05	0.000464	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GPX1—head and neck cancer	8.26e-05	0.000458	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP1A1—head and neck cancer	8.18e-05	0.000453	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TYMS—head and neck cancer	8.13e-05	0.000451	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTM1—head and neck cancer	8.04e-05	0.000445	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTEN—head and neck cancer	7.99e-05	0.000443	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—YAP1—head and neck cancer	7.94e-05	0.00044	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GPX1—head and neck cancer	7.7e-05	0.000427	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP1A1—head and neck cancer	7.62e-05	0.000422	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	7.18e-05	0.000398	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CA—head and neck cancer	6.7e-05	0.000371	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2—head and neck cancer	6.2e-05	0.000344	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CA—head and neck cancer	5.64e-05	0.000312	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2—head and neck cancer	5.63e-05	0.000312	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—head and neck cancer	5.47e-05	0.000303	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—head and neck cancer	4.86e-05	0.000269	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOTCH1—head and neck cancer	4.83e-05	0.000268	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TYMS—head and neck cancer	4.77e-05	0.000264	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTM1—head and neck cancer	4.71e-05	0.000261	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—head and neck cancer	4.6e-05	0.000255	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—head and neck cancer	4.53e-05	0.000251	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAPK3—head and neck cancer	4.53e-05	0.000251	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GPX1—head and neck cancer	4.51e-05	0.00025	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP1A1—head and neck cancer	4.47e-05	0.000248	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAPK1—head and neck cancer	4.31e-05	0.000239	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—head and neck cancer	4.31e-05	0.000239	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTEN—head and neck cancer	4.24e-05	0.000235	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CA—head and neck cancer	4.11e-05	0.000228	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTEN—head and neck cancer	3.95e-05	0.000219	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CA—head and neck cancer	3.74e-05	0.000207	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—head and neck cancer	3.46e-05	0.000192	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	3.36e-05	0.000186	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2—head and neck cancer	3.33e-05	0.000184	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—head and neck cancer	3.24e-05	0.00018	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTEN—head and neck cancer	3.13e-05	0.000173	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—head and neck cancer	3.05e-05	0.000169	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CA—head and neck cancer	2.99e-05	0.000166	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—head and neck cancer	2.83e-05	0.000157	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT3—head and neck cancer	2.8e-05	0.000155	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CA—head and neck cancer	2.79e-05	0.000155	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK3—head and neck cancer	2.67e-05	0.000148	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—head and neck cancer	2.66e-05	0.000147	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK1—head and neck cancer	2.54e-05	0.000141	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—head and neck cancer	2.54e-05	0.000141	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—head and neck cancer	2.44e-05	0.000135	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTEN—head and neck cancer	2.32e-05	0.000128	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—head and neck cancer	2.28e-05	0.000126	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	2.21e-05	0.000122	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—head and neck cancer	2.14e-05	0.000118	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—head and neck cancer	2.04e-05	0.000113	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—head and neck cancer	1.8e-05	9.99e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CA—head and neck cancer	1.63e-05	9.06e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—head and neck cancer	1.33e-05	7.4e-05	CbGpPWpGaD
